Citadel Advisors’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Citadel Advisors’s Portfolio IMUC Stock Details IMUC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-25	Closed	-$1K	–	8864
2014 Q2	$1K	Sell	25 -158	-86%	-$7.62K	﹤0.01%	7917
2014 Q1	$9K	Sell	183 -650	-78%	-$31.8K	﹤0.01%	7569
2013 Q4	$31K	Buy	833 +495	+146%	+$46.9K	﹤0.01%	6272
2013 Q3	$35K	Buy	+338	New	+$37.1K	﹤0.01%	5970

Other funds holding IMUC

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Citadel Advisors's IMUC Position: Q4 2018 in Review

Citadel Advisors sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2018, closing a stake of 69,746 shares — an estimated $15K sold.

Citadel Advisors first reported a position in IMUC in Q3 2013 and held it in 12 quarters. The position peaked at $99K in Q1 2018. 3 funds tracked by Wall St. Rank hold IMUC as of Q4 2018.

Citadel Advisors reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2018 after selling out during the quarter.
Citadel Advisors sold 69,746 ImmunoCellular Therapeutics, Ltd. shares in Q4 2018, an estimated $15K.
Citadel Advisors first reported a position in ImmunoCellular Therapeutics, Ltd. in Q3 2013 and held it in 12 quarters.
Citadel Advisors's ImmunoCellular Therapeutics, Ltd. position peaked at $99K in Q1 2018.
3 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2018.

Based on Citadel Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.